Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study
Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpen · 2026
Read Envonalkib Versus Crizotinib in Treatment‐Naive ALK‐Positive Non‐Small Cell Lung Cancer: Final Efficacy and Biomarker Analyses of the Randomized Phase III Study by Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13634175.txt.
Description
Jie Huang and a large co-author team report final results, in 2026 work, from a large trial of two drugs for a form of lung cancer driven by one gene fault. Patients new to treatment were split by lot between a newer drug and an older standard. The chief aim was time before the cancer grew again.
More than two hundred sixty patients took part, with follow-up near four years. The newer drug held the cancer back far longer, with a mid time more than twice that of the standard. Blood tests for tumour DNA showed that patients with extra faults in guard genes fared worse. After growth returned, set escape routes showed in about a fourth of cases. Survival data are still young, the team notes.
Catalog record
| CREATOR | Jie Huang, Yuanyuan Wang, Haishuang Sun, Jie Min, Nong Yang, Qitao Yu, Ying Cheng, Yanqiu Zhao, Manxiang Li, Hong Chen, Shouan Ren, Jianying Zhou, Wu Zhuang, Xintian Qin, Lejie Cao, Yan Yu, Jian Zhang, Jianxing He, Jifeng Feng, Hao Yu, Lin Zhang, Xinyuan Zhao, Wenfeng Fang, Jing Li, Li Zhang, Yunpen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 39 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |